ESSA Pharma Inc. (EPIX)
| Market Cap | 9.23M -96.8% |
| Revenue (ttm) | n/a |
| Net Income | -25.27M |
| EPS | -0.57 |
| Shares Out | 47.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 0.2012 |
| Day's Range | n/a |
| 52-Week Range | 0.1800 - 6.4500 |
| Beta | 1.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2025 |
About EPIX
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.
Financial Performance
Financial StatementsNews
ESSA Announces Completion of Arrangement with XenoTherapeutics
SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada , Oct. 9, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherapeutics' (...
ESSA Securityholders Approve Acquisition by XenoTherapeutics
SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada , Oct. 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defined below...
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October...
Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025
Adjournment to provide time for continued discussions regarding possible revised financial terms of transaction with XenoTherapeutics SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.
Essa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash Distribution
SOUTH SAN FRANCISCO, Calif and VANCOUVER, BC , Aug. 25, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) announced on August 14, 2025 that, in connection with the Compan...
Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Aug. 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with the Company's recently...
Essa Pharma Inc. Announces US$80 Million Cash Distribution to Shareholders
SOUTH SAN FRANCISCO, Calif and VANCOUVER, Canada , Aug. 6, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, following the Company's receipt of an o...
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 23, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announc...
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif.
ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025
Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," o...
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada , March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of ...
ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024
Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 11, 2025 /PRNewswire/ - ESSA Pharma Inc. ...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Dec. 17, 2024 /PRNewswire/ - ESS...